Management of febrile neutropenia in solid tumours and lymphomas using the Multinational Association for Supportive Care in Cancer (MASCC
) risk index: feasibility and safety in routine clinical practice.
(17.) Lacouture ME, Maitland ML, Segaert S, et al: A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC
skin toxicity study group.
More recently, low-level laser therapy has been accepted as a valuable treatment option for OM by the MASCC
(Multinational Association of Supportive Care in Cancer) and ISOO (International Society for Oral Oncology) [Keefe et al., 2007].
Antiemetics: an update and the MASCC
guidelines applied in clinical practice.
Importantly, the Multinational Association of Supportive Care in Cancer (MASCC
) recently published a position statement that emphasizes the importance of adequate and integral supportive care, defined as management of both physical and psychological symptoms from diagnosis through the entire survivorship period (27).
It is the only drug of its class specifically recommended by the European Society of Medical Oncology (ESMO), and the Multinational Association of Supportive Care in Cancer (MASCC
), for moderately emetogenic chemotherapy3.
In 2005, a panel of experts from the Multinational Association of Supportive Care in Cancer (MASCC
) and the International Society of Oral oncology reviewed the literature to create evidence-based guidelines for preventing, evaluating and treating oral mucositis, a summary of which can be found at www.MASCC.org (see list of resources).
En el ano 2000, Klastersky y colaboradores (25) publicaron el modelo de prediccion de riesgo de la Multinational Association for Supportive Care in Cancer (MASCC
), basado en un estudio que analizo cerca de 1.000 episodios de neutropenia febril (Tabla no.
MPC, maximum permitted concentration; MASCC
, maximum allowable soil contaminant concentration
An oral history of MASCC
, its origin and development from MASCC
's beginnings to 2009.
Secondly, more reliable and valid instruments for CINV assessment such as the Functional Living Index Emesis (FLIE), MANE, MASCC
Antiemesis Tool (MAT), or Index of Nausea, Vomiting, and Retching (INVR) should be considered in future studies .
Desde la conferencia de consenso de la Multinacional Association of Supportive Care of Cancer (MASCC
) celebrada en Perugia en el ano 2004 (15), la mayoria de los autores aceptan la clasificacion de los citostaticos o combinaciones de ellos en funcion del riesgo emetogeno en farmacos de alto, moderado, bajo o minimo riesgo emetogeno (tabla 1).